NOX Inhibitors: From Bench to Naxibs to Bedside.

Area of Science:

• Biochemistry
• Cellular Biology
• Pharmacology

Background:

• Reactive oxygen species (ROS) are crucial signaling molecules, but their dysregulation contributes to pathophysiology.
• Conventional antioxidant therapies have failed due to non-selective ROS scavenging, impacting both physiological and pathological ROS.
• A new strategy focuses on selectively targeting disease-relevant enzymatic ROS sources.

Purpose of the Study:

• To review the alternative approach of targeting specific enzymatic sources of ROS.
• To highlight NADPH oxidases (NOX) as key drug targets due to their primary role in ROS production.
• To discuss the development and clinical relevance of NOX inhibitors.

Main Methods:

• Review of literature on ROS-producing enzymes and their role in disease.
• Analysis of NADPH oxidase (NOX) family members (NOX1-5, DUOX1-2) and their functions.
• Focus on clinically validated NOX inhibitors and their therapeutic applications.

Main Results:

• NADPH oxidases (NOX) are identified as primary targets for therapeutic intervention in ROS-related diseases.
• The WHO has recognized NADPH oxidase inhibitors (naxib) as a new therapeutic class.
• Clinical trials are underway for setanaxib, a first-in-class NOX inhibitor.

Conclusions:

• Selective inhibition of NOX enzymes represents a promising therapeutic strategy, overcoming limitations of traditional antioxidants.
• NOX inhibitors offer a targeted approach to manage diseases associated with ROS dysregulation.
• Further research and clinical validation of NOX inhibitors are crucial for therapeutic advancement.